Rheumatology Lab Tests Interpretation: A Guide for Physicians

Autoimmunity occurs when the immune system develops responses against self-antigens rather than foreign pathogens. The immune system normally distinguishes between self and non-self components, but this discrimination can fail, leading to attacks on the body's own cells and organs. Autoimmune diseases are rare, indicating that the immune system's discrimination capabilities are nearly perfect. There are four main mechanisms that can lead to autoimmunity: (1) Genetic mutations - stable changes in DNA nucleotide sequences that alter protein structure and behavior, causing the immune system to recognize mutated proteins as foreign; (2) Release of sequestered antigens - proteins separated from the immune system during embryonic development that, if released into circulation, are recognized as foreign; (3) Activation of autoreactive B and T cells - cells that escape normal tolerance mechanisms and are accidentally activated by mitogens; (4) Molecular mimicry - when pathogen proteins share structural similarities with host proteins, causing cross-reactive immune responses.

Autoimmunity occurs when the immune system fails to distinguish between self and non-self, leading to self-destructive attacks on the body's own tissues. Under normal conditions, the immune system identifies foreign pathogens while tolerating the body's own cells through a mechanism called immune tolerance. When this discrimination ability breaks down, immune cells and antibodies mistakenly attack the body's own cells, proteins, and organs, causing structural and functional damage. The term 'autoimmunity' literally means 'protection against self,' but paradoxically results in injury to self rather than protection.

An antigen is any substance the immune system can recognize, but recognition does not always lead to attack. Antigens are classified as self-antigens (body's own cells and proteins, which must be tolerated) or non-self antigens (foreign substances like food, medications, and microorganisms). Non-self antigens are further divided into pathogenic (causing disease, like viruses and bacteria) and non-pathogenic (harmless, like jewelry and food). The immune system must discriminate between self and non-self, and between pathogenic and non-pathogenic antigens. When this discrimination fails, autoimmune diseases occur, where the immune system attacks the body's own tissues, as seen in Type 1 diabetes, multiple sclerosis, and lupus.

Autoimmunity is defined as an immune response against self-substances present in the body, including proteins, lipids, carbohydrates, and nucleic acids. These self-substances act as potential antigens called self-antigens. When an immune response is mounted against these self-antigens and causes adverse effects, it is termed autoimmunity. The antibodies formed against such self-antigens are known as autoantibodies.

The immune system differentiates between self and non-self entities. Antibodies and T cells recognize foreign antigens like bacteria and viruses. When these components fail to recognize self and generate responses against the body's own cells, they become self-reactive. Self-reactive T cells and autoantibodies that recognize self cells form the basis of autoimmunity. Immunological tolerance is a crucial mechanism that removes self-reactive cells through central tolerance (elimination during B and T cell maturation) and peripheral tolerance (elimination in peripheral lymphoid organs through apoptosis). This serves as a safeguard mechanism. Autoimmunity occurs when tolerance mechanisms fail, leading to severe organ damage. The term was first used by Paul Ehrlich to describe self-toxicity. Autoimmune disorders are classified into organ-specific (targeting single organ antigens) and systemic (targeting multiple tissues and organs).

Rheumatoid Arthritis, the most common autoimmune rheumatic disease, causes joint inflammation where the immune system attacks cartilage, frequently affecting small hand joints and wrists with morning stiffness. While no cure exists, treatments can control the disease allowing normal, productive lives. Systemic Lupus Erythematosus is a prototype autoimmune disease characterized by periods of activity and remission, with antinuclear antibodies as a key laboratory finding. It can affect multiple organs including kidneys, blood vessels, and nervous system, presenting with diverse symptoms like hypertension, leg swelling, or numbness.

Rheumatology encompasses bone and metabolic diseases, genetic disorders, autoimmune conditions, and autoinflammatory diseases. Autoimmunity occurs when internal tolerance breaks down, causing the immune system to attack the body's own tissues. Major autoimmune diseases include: Rheumatoid arthritis (most studied, chronic progressive systemic inflammatory disease affecting synovial membranes, classic 'rheumatoid hand' features, diagnostic criteria evolved from 1987 to 2010), Sjögren's syndrome (dry eyes and mouth, differential diagnosis includes HIV and medications, anti-Ro/La antibodies), Systemic lupus erythematosus (multisystem disease affecting skin, CNS, heart-lung axis, kidneys, diagnostic criteria evolved from 1982 to 2019, key autoantibodies include anti-dsDNA, anti-Sm, anti-Ro/La), Antiphospholipid syndrome (thrombotic and autoimmune condition causing valvular disease, thrombocytopenia, livedo reticularis, digital ulcers, diagnostic criteria require clinical and laboratory criteria), Scleroderma (systemic sclerosis with localized and systemic forms, key differentiator is trunk skin thickening, capillaroscopy revolutionized diagnosis, anti-Scl-70 and anti-centromere antibodies), Inflammatory myopathies (proximal muscle-inflammation diseases, polymyositis and dermatomyositis distinguished by cutaneous manifestations like heliotrope rash and Gottron's papules, anti-synthetase syndrome is a specific subset with interstitial lung disease and mechanic's hands).

This comprehensive lecture covers the major autoimmune diseases of connective tissue, including Systemic Lupus Erythematosus (SLE), Antiphospholipid Syndrome (APS), Systemic Sclerosis, Sjögren's Syndrome, and Myositis (Polymyositis and Dermatomyositis). The key teaching points include: SLE is characterized by photosensitivity, malar rash, cytopenias, and renal involvement (lupus nephritis), with anti-dsDNA and anti-Sm antibodies being highly specific markers; APS presents with arterial/venous thrombosis and obstetric complications, diagnosed by persistent positive anticardiolipin, lupus anticoagulant, or anti-beta2 glycoprotein I antibodies; Systemic Sclerosis shows skin thickening, Raynaud's phenomenon, and GI involvement, with limited form associated with anti-centromere antibodies and diffuse form with anti-Scl-70 antibodies; Sjögren's Syndrome features sicca symptoms (dry eyes and mouth) and lymphocytic infiltration of exocrine glands, with minor salivary gland biopsy showing focal lymphocytic sialadenitis as the gold standard; Myositis presents with proximal muscle weakness, with dermatomyositis distinguished by pathognomonic skin lesions (Gottron's papules and heliotrope rash) and increased malignancy risk in adults.

Connective tissue diseases (conectivopatías) are a heterogeneous group of chronic autoimmune conditions including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, ankylosing spondylitis, rheumatic fever, Sjögren's syndrome, and myositis. These diseases share common etiopathogenic substrates, similar histopathological patterns, comparable clinical presentations, and coincident therapeutic bases. Rheumatoid arthritis is a chronic inflammatory systemic disease of unknown etiology affecting articular joints bilaterally and symmetrically, with destruction of articular and periarticular structures. It affects all races with 8 cases per 1,000 inhabitants, showing 3:1 female predominance, typically presenting between ages 30-60. Etiopathogenesis involves genetic factors (familial clustering, HLA-DR4 in 70% of patients), infectious factors, and autoimmune mechanisms (cellular cytokine production including IL-1, TNF, GM-CSF, and humoral factors like rheumatoid factor and complement activation). Clinical manifestations include articular forms (insidious onset, acute onset, articular attacks) and extra-articular forms (subcutaneous nodules, pleural effusion, pulmonary nodules, pericarditis, Felty's syndrome). Characteristic hand deformities include 'hand in funnel,' 'hand in claw,' 'swan neck,' 'boutonniere,' and 'Z-thumb.' Diagnostic criteria require four of: morning stiffness >1 hour, arthritis in 3+ joint areas, involvement of wrist/MCP/PIP joints, symmetric arthritis, rheumatoid nodules, positive RF, and radiological changes. Treatment includes NSAIDs, DMARDs (gold salts, penicillamine, methotrexate, sulfasalazine), and rehabilitation therapy. Systemic lupus erythematosus is a chronic autoimmune disease of unknown etiology affecting connective tissue in vascular system, dermis, serous membranes, kidneys, and joints. It primarily affects females (8:1 ratio) between ages 16-55. Pathogenesis involves genetic, immunological, environmental, and hormonal factors causing loss of self-tolerance, producing autoantibodies and circulating immune complexes. Clinical manifestations include malar rash, oral ulcers, alopecia, arthritis, tenosynovitis, pleuritis, Libman-Sacks endocarditis, Raynaud's phenomenon, and various glomerulonephritis types. Neurological manifestations include psychosis, seizures, and peripheral neuropathy. Hematological manifestations include anemia, leukopenia, thrombocytopenia, lymphadenopathy, and splenomegaly. SLE diagnosis uses American Rheumatology Association criteria combining clinical and humoral findings. Essential studies include hemogram (anemia, leukopenia, lymphopenia, thrombocytopenia), accelerated ESR, positive ANA, false positive VDRL, anti-DNA/anti-Sm antibodies, decreased complement levels (C3, C4, CH50), and characteristic skin biopsy findings. SLE is chronic without curative treatment, with 70% survival at 20 years, characterized by remission-exacerbation cycles. Disease activity indicators include fever, fatigue, weight loss, arthritis, edema, hair loss, oliguria, and abnormal menstruation. Laboratory markers include anemia, thrombocytopenia, accelerated ESR, proteinuria, hyperazotemia, and decreased complement factors. Treatment must be individualized, considering risk-benefit ratios, with objectives to maintain organ function and prevent permanent damage. General measures include avoiding sulfas, penicillins, and hormonal contraceptives; light exercises for fatigue; sun avoidance; and influenza/pneumococcal vaccination. Treatment for active disease includes NSAIDs, antimalarials, and steroids for fever/arthritis; indomethacin or steroids for serositis; oral/IV steroids or immunosuppressants for renal involvement; and steroids, IV gammaglobulin, or splenectomy for hematological manifestations. CNS involvement requires steroids, anticonvulsants, and immunosuppressants. Prognosis has improved with 90% survival at 10 years, though CNS involvement, hypertension, and hyperazotemia indicate poor prognosis.

This comprehensive section covers two major autoimmune diseases. Systemic Lupus Erythematosus (SLE) is the prototype autoimmune disease, a chronic condition affecting skin, joints, kidneys, and serous membranes with prevalence of 30-50 per 100,000 and female-to-male ratio of 7:1 until age 65. Pathogenesis involves failures in auto-tolerance: increased apoptosis with inadequate clearance, defective apoptotic body recognition, and accumulation of nuclear fragments recognized as autoantigens. Lupus nephritis is classified into six classes (1-6) based on histological findings, with Class 3 and 4 associated with nephrotic syndrome. The 2019 EULAR/ACR classification criteria require ANA positivity (98% of patients) and at least one clinical or immunological criterion. Rheumatoid arthritis is a chronic autoimmune and degenerative disease with prevalence of 1%, typically appearing between ages 40-70 with female-to-male ratio of 3:1. The main genetic factor is HLA-DR4 polymorphism. Pathogenesis begins with T cell activation by unknown environmental antigens, leading to synovial inflammation and joint destruction. The American College of Rheumatology diagnostic criteria require clinical features, joint involvement score ≥6, serological evidence, elevated acute phase reactants, and symptom duration ≥6 weeks.

This video explains the core principles of diagnostic testing and screening in biostatistics, covering key concepts including the 2x2 table framework for diagnostic tests, sensitivity (true positive rate), specificity (true negative rate), positive predictive value, and negative predictive value, along with their relationships to disease prevalence; ROC curves for evaluating diagnostic accuracy; screening versus confirmatory tests (using the SNOUT and SPIN mnemonics); and probability concepts including likelihood ratios, Bayes' theorem, and decision trees for clinical decision-making.

Pre-test probability is the likelihood a patient has a condition before testing, based on symptoms, risk factors, and exposure history. Bayes' Theorem provides a framework for updating this probability based on test results. Sensitivity is the proportion of true positive cases correctly identified, while specificity is the proportion of true negative cases correctly identified. False positive rates occur when tests incorrectly identify healthy people as having conditions. In low-prevalence populations, even accurate tests produce many false positives. The same test result can mean very different things depending on pre-test probability. A positive test in a low-risk patient is more likely to be a false positive than in a high-risk patient.

In diagnostic testing, sensitivity (true positive rate) is useful for ruling out a disease because high sensitivity means few false negatives, while specificity (true negative rate) is useful for confirming a disease because high specificity means few false positives; the predictive values (positive and negative) depend on disease prevalence and represent the post-test probability of having or not having the disease, with likelihood ratios serving as synthetic tools that combine sensitivity and specificity to quantify how much a test changes the probability of disease.

Sensitivity measures a test's ability to correctly identify those with the disease (true positives), while specificity measures its ability to correctly identify those without (true negatives). Even a 95% sensitive test misses 1 in 20 with the disease. There's always a trade-off—highly sensitive tests minimize false negatives but generate more false positives, making them good rule-out tests. The probability a person has a disease after a test depends on pre-test probability, sensitivity, and specificity. Pre-test probability is the clinician's estimate based on prevalence and individual factors. A normal test result doesn't always exclude disease—when pre-test probability is very high, even good tests may miss cases. This illustrates that test results shift probability but don't always definitively confirm or exclude disease.

Sensitivity measures the proportion of true positive cases correctly identified by a diagnostic test (true positive / [true positive + false negative]), while specificity measures the proportion of true negative cases correctly identified (true negative / [true negative + false positive]); sensitivity rules out disease when negative (high sensitivity means few false negatives), whereas specificity rules in disease when positive (high specificity means few false positives).